| | Variable | Training group (n=60) | Validation group (n=29) | T/ | P value |
| | Age, y | 51.7±12.7 | 57.8±10.7 | -2.238 | 0.028 | | Gender (male, female) | 50/10 | 26/3 | 0.222 | 0.637 | | BMI, Kg/m2 | 22.7±3.7 | 23.2±2.5 | -0.649 | 0.518 | | PLT,/L | 195.9±142.6 | 138.1±79.3 | 2.031 | 0.045 | | ALB, g/L | 40.7±6.0 | 40.0±4.2 | 0.660 | 0.511 | | TB, umol/L | 18.0±22.1 | 13.6±14.9 | 0.957 | 0.341 | | ALT, U/L | 60.0±77.1 | 47.4±43.4 | 0.816 | 0.417 | | AST, U/L | 64.2±97.2 | 40.7±30.0 | 1.270 | 0.208 | | GGT, U/L | 107.8±193.5 | 88.7±95.5 | 0.502 | 0.617 | | PT, S | 13.7±1.0 | 13.7±1.0 | -0.053 | 0.958 | | PTA, % | 93.6±12.8 | 90.5±12.0 | 1.090 | 0.279 | | Liver Function Grading (A/B) | 58/2 | 28/1 | - - - | 1.000 | | HBV DNA(<10e3, ≥ 10e3IU/mL) | 46/14 | 19/10 | 1.234 | 0.267 | | AFP(≤400,>400ng/ml) | 45/15 | 22/7 | 0.008 | 0.930 | | HCV (Absent, Present) | 59/1 | 28/1 | - - - | 0.548 | | Tumor size, cm | 6.0±3.9 | 5.0±3.7 | 1.092 | 0.278 | | CT value in unenhanced phase (≤42.5,>42.5) | 28/32 | 6/23 | 5.588 | 0.018 | | CT value in artery phase(≤66.5,>66.5) | 20/40 | 9/20 | 0.047 | 0.828 | | CT value in venous phase(≤102,>102) | 44/16 | 20/9 | 0.185 | 0.667 | | CT value in delayed phase(≤103.5,>103.5) | 51/9 | 24/5 | 0.002 | 0.970 | | Located in the left lobe (Absent, Present) | 44/16 | 20/9 | 0.185 | 0.667 | | Capsule (Absent, Present) | 44/16 | 25/4 | 1.860 | 0.173 | | With smooth margin (Absent, Present) | 51/9 | 18/11 | 5.901 | 0.015 | | Peritumoral enhancement (Absent, Present) | 47/13 | 24/5 | 0.237 | 0.626 | | Visible small blood vessel (Absent, Present) | 21/39 | 15/14 | 2.270 | 0.132 | | The distance from the IVC | 3.2±2.3 | 4.2±2.6 | -1.540 | 0.127 | | The distance from the portal vein branches | 3.6±2.3 | 5.0±2.5 | -1.770 | 0.080 | | Liver cirrhosis (Absent, Present) | 35/25 | 16/13 | 0.080 | 0.778 | | MVI (Absent, Present) | 32/28 | 16/13 | 0.027 | 0.870 |
|
|
